Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 3/2017

31.07.2017

Intermediate term thrombotic risk in contemporary total cavo-pulmonary connection for single ventricle circulations

verfasst von: Jenna M. Faircloth, Olivia Roe, Tarek Alsaied, Joseph S. Palumbo, Alexander Vinks, Gruschen R. Veldtman

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Despite the common occurrence of thrombosis in Fontan circulations, the mid-term thrombotic risk beyond the first two postoperative years is poorly defined especially in total cavo pulmonary Fontan. This study examines the thrombotic incidence and risk beyond the first 2 years after contemporary Fontan surgery. Using a retrospective cohort study design, 89 Fontan patients, 50 male, were included and evaluated with a median of 8.3 years (IQR 6.8–11.4) follow-up. Hospital records were reviewed for known risk factors of thrombosis, thrombotic events, antiplatelet and anticoagulation management, and basic characteristics. Forty seven patients (52%) had a dominant left ventricle, and 28 (32%) had hypoplastic left heart syndrome. Eight patients had thrombotic events post Fontan surgery at a median age of 9 years (IQR 5.6–13), 5.7 (IQR 2.0–9.7) years following surgery, not including events that occurred immediately peri-operatively. Four thrombotic events were intracardiac whereas the remainder were extra-cardiac. There was no significant univariate correlation between thrombosis and the presence of ventricular morphology, pulmonary arterial reconstruction, or type of cavopulmonary anastomosis (lateral tunnel vs. extracardiac conduit). Thrombosis continues to be an important intermediate-term risk even for patients with contemporary Fontan circulations. These results strongly suggest that thrombophilic risk is not dictated purely by vascular pathway and hemodynamic variables. Further investigation into the pathophysiology, individualized risk, and effectiveness of anticoagulation strategies are required in this high risk population.
Literatur
1.
Zurück zum Zitat Alsaied T, Alsidawi S, Allen CC, Faircloth J, Palumbo JS, Veldtman GR (2015) Strategies for thromboprophylaxis in Fontan circulation: a meta-analysis. Heart 101:1731–1737CrossRefPubMed Alsaied T, Alsidawi S, Allen CC, Faircloth J, Palumbo JS, Veldtman GR (2015) Strategies for thromboprophylaxis in Fontan circulation: a meta-analysis. Heart 101:1731–1737CrossRefPubMed
2.
Zurück zum Zitat Mondesert B, Marcotte F, Mongeon FP et al (2013) Fontan circulation: success or failure?. Can J Cardiol 29:811–820CrossRefPubMed Mondesert B, Marcotte F, Mongeon FP et al (2013) Fontan circulation: success or failure?. Can J Cardiol 29:811–820CrossRefPubMed
3.
Zurück zum Zitat Monagle P, Cochrane A, Roberts R et al (2011) A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children. J Am Coll Cardiol 58:645–651CrossRefPubMed Monagle P, Cochrane A, Roberts R et al (2011) A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children. J Am Coll Cardiol 58:645–651CrossRefPubMed
4.
Zurück zum Zitat Monagle P, Cochrane A, McCrindle B, Benson L, Williams W, Andrew M (1998) Thromboembolic complications after fontan procedures-the role of prophylactic anticoagulation. J Thorac Cardiovasc Surg 115:493–498CrossRefPubMed Monagle P, Cochrane A, McCrindle B, Benson L, Williams W, Andrew M (1998) Thromboembolic complications after fontan procedures-the role of prophylactic anticoagulation. J Thorac Cardiovasc Surg 115:493–498CrossRefPubMed
5.
Zurück zum Zitat Khairy P, Fernandes SM, Mayer JE Jr et al (2008) Long-term survival, modes of death, and predictors of mortality in patients with Fontan surgery. Circulation 117:85–92CrossRefPubMed Khairy P, Fernandes SM, Mayer JE Jr et al (2008) Long-term survival, modes of death, and predictors of mortality in patients with Fontan surgery. Circulation 117:85–92CrossRefPubMed
6.
Zurück zum Zitat Jahangiri M, Shore D, Kakkar V, Lincoln C, Shinebourne E (1997) Coagulation factor abnormalities after the Fontan procedure and its modifications. J Thorac Cardiovasc Surg 113:989–992. Discussion 992-3 CrossRefPubMed Jahangiri M, Shore D, Kakkar V, Lincoln C, Shinebourne E (1997) Coagulation factor abnormalities after the Fontan procedure and its modifications. J Thorac Cardiovasc Surg 113:989–992. Discussion 992-3 CrossRefPubMed
7.
Zurück zum Zitat Marrone C, Galasso G, Piccolo R et al (2011) Antiplatelet versus anticoagulation therapy after extracardiac conduit Fontan: a systematic review and meta-analysis. Pediatr Cardiol 32:32–39CrossRefPubMed Marrone C, Galasso G, Piccolo R et al (2011) Antiplatelet versus anticoagulation therapy after extracardiac conduit Fontan: a systematic review and meta-analysis. Pediatr Cardiol 32:32–39CrossRefPubMed
8.
Zurück zum Zitat Chaloupecky V, Svobodova I, Hadacova I et al (2005) Coagulation profile and liver function in 102 patients after total cavopulmonary connection at mid term follow up. Heart 91:73–79 Chaloupecky V, Svobodova I, Hadacova I et al (2005) Coagulation profile and liver function in 102 patients after total cavopulmonary connection at mid term follow up. Heart 91:73–79
9.
Zurück zum Zitat Binotto MA, Maeda NY, Lopes AA (2008) Altered endothelial function following the Fontan procedure. Cardiol Young 18:70–74CrossRefPubMed Binotto MA, Maeda NY, Lopes AA (2008) Altered endothelial function following the Fontan procedure. Cardiol Young 18:70–74CrossRefPubMed
10.
Zurück zum Zitat Binotto MA, Maeda NY, Lopes AA (2005) Evidence of endothelial dysfunction in patients with functionally univentricular physiology before completion of the Fontan operation. Cardiol Young 15:26–30CrossRefPubMed Binotto MA, Maeda NY, Lopes AA (2005) Evidence of endothelial dysfunction in patients with functionally univentricular physiology before completion of the Fontan operation. Cardiol Young 15:26–30CrossRefPubMed
11.
Zurück zum Zitat Kajimoto H, Nakazawa M, Murasaki K, Hagiwara N, Nakanishi T (2009) Increased P-selectin expression on platelets and decreased plasma thrombomodulin in Fontan patients. Circ J 73:1705–1710CrossRefPubMed Kajimoto H, Nakazawa M, Murasaki K, Hagiwara N, Nakanishi T (2009) Increased P-selectin expression on platelets and decreased plasma thrombomodulin in Fontan patients. Circ J 73:1705–1710CrossRefPubMed
12.
Zurück zum Zitat McCrindle BW, Manlhiot C, Cochrane A et al (2013) Factors associated with thrombotic complications after the Fontan procedure: a secondary analysis of a multicenter, randomized trial of primary thromboprophylaxis for 2 years after the Fontan procedure. J Am Coll Cardiol 61:346–353CrossRefPubMed McCrindle BW, Manlhiot C, Cochrane A et al (2013) Factors associated with thrombotic complications after the Fontan procedure: a secondary analysis of a multicenter, randomized trial of primary thromboprophylaxis for 2 years after the Fontan procedure. J Am Coll Cardiol 61:346–353CrossRefPubMed
13.
Zurück zum Zitat Coon PD, Rychik J, Novello RT, Ro PS, Gaynor JW, Spray TL (2001) Thrombus formation after the Fontan operation. Ann Thorac Surg 71:1990–1994CrossRefPubMed Coon PD, Rychik J, Novello RT, Ro PS, Gaynor JW, Spray TL (2001) Thrombus formation after the Fontan operation. Ann Thorac Surg 71:1990–1994CrossRefPubMed
14.
Zurück zum Zitat Kalbfleisch JD, Lawless JF, Vollmer WM (1983) Estimation in Markov models from aggregate data. Biometrics 39:907–919CrossRefPubMed Kalbfleisch JD, Lawless JF, Vollmer WM (1983) Estimation in Markov models from aggregate data. Biometrics 39:907–919CrossRefPubMed
15.
Zurück zum Zitat Jahangiri M, Kreutzer J, Zurakowski D, Bacha E, Jonas RA (2000) Evaluation of hemostatic and coagulation factor abnormalities in patients undergoing the Fontan operation. J Thorac Cardiovasc Surg 120:778–782CrossRefPubMed Jahangiri M, Kreutzer J, Zurakowski D, Bacha E, Jonas RA (2000) Evaluation of hemostatic and coagulation factor abnormalities in patients undergoing the Fontan operation. J Thorac Cardiovasc Surg 120:778–782CrossRefPubMed
16.
Zurück zum Zitat Odegard KC, McGowan FX Jr, Zurakowski D et al (2003) Procoagulant and anticoagulant factor abnormalities following the Fontan procedure: increased factor VIII may predispose to thrombosis. J Thorac Cardiovasc Surg 125:1260–1267CrossRefPubMed Odegard KC, McGowan FX Jr, Zurakowski D et al (2003) Procoagulant and anticoagulant factor abnormalities following the Fontan procedure: increased factor VIII may predispose to thrombosis. J Thorac Cardiovasc Surg 125:1260–1267CrossRefPubMed
17.
Zurück zum Zitat Tomkiewicz-Pajak L, Wojcik T, Chlopicki S et al (2014) Aspirin resistance in adult patients after Fontan surgery. Int J Cardiol 181C:19–26 Tomkiewicz-Pajak L, Wojcik T, Chlopicki S et al (2014) Aspirin resistance in adult patients after Fontan surgery. Int J Cardiol 181C:19–26
18.
Zurück zum Zitat Tomkiewicz-Pajak L, Hoffman P, Trojnarska O, Lipczynska M, Podolec P, Undas A (2014) Abnormalities in blood coagulation, fibrinolysis, and platelet activation in adult patients after the Fontan procedure. J Thorac Cardiovasc Surg 147:1284–1290CrossRefPubMed Tomkiewicz-Pajak L, Hoffman P, Trojnarska O, Lipczynska M, Podolec P, Undas A (2014) Abnormalities in blood coagulation, fibrinolysis, and platelet activation in adult patients after the Fontan procedure. J Thorac Cardiovasc Surg 147:1284–1290CrossRefPubMed
Metadaten
Titel
Intermediate term thrombotic risk in contemporary total cavo-pulmonary connection for single ventricle circulations
verfasst von
Jenna M. Faircloth
Olivia Roe
Tarek Alsaied
Joseph S. Palumbo
Alexander Vinks
Gruschen R. Veldtman
Publikationsdatum
31.07.2017
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 3/2017
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-017-1530-0

Weitere Artikel der Ausgabe 3/2017

Journal of Thrombosis and Thrombolysis 3/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.